BCHE and Alzheimer disease: Three of the four FDA-approved anti-AD medications temporarily ameliorate AD symptoms by inhibiting cholinesterases (ChEs), whereby donepezil and galantamine are selective acetylcholinesterase (AChE) inhibitors and rivastigmine additionally binds to the isoenzyme butyrylcholinesterase (BChE).